Directorate Change
Summary by AI BETAClose X
Optima Health plc
("Optima", the "Company", and, together with its subsidiaries, the "Group")
Directorate Change
LONDON, UK, 23 March 2026, Optima Health (AIM: OPT), the UK's leading provider of technology enabled corporate health and wellbeing solutions, today announces that Heidi Giles, Chief Financial Officer, will leave the Company on 31 July 2026. Subject to the successful completion of the recently announced acquisition of PAM Healthcare, Optima will appoint Andrew Bones as Interim Chief Financial Officer. Heidi remains a director of the Company during this period, and will continue to fulfil her current role facilitating a smooth transition. Further announcements will be made as appropriate.
Jonathan Thomas, Chief Executive Officer of Optima Health, said: "Heidi has made a significant contribution to the success of Optima Health, bringing professionalism, expertise, and rigour to our financials and through wider support throughout the business. Heidi's committed and diligent work was fundamental to Optima executing the IPO in 2024, and the strong strategic progress made since, and leaves a strong platform for our future success. Heidi has been a great colleague and business partner, and I thank her for her service to Optima Health and wish her nothing but the best in her future."
Enquiries
|
|
About Optima Health
Optima Health is the UK's leading provider of occupational health and wellbeing services, directly influencing and improving people's lives for 25 years. Optima Health's incredible team of professionals quickly and effectively encapsulate client's needs, supporting organisations of all shapes and sizes. Through tailored solutions and innovative systems, Optima Health offers unparalleled clinical expertise to its clients. These solutions ensure that processes are simple and allow its clients to spend more time focusing on their employees driving a healthy, high-performing workplace. For more information visit www.optima health.co.uk
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 30 minutes ago BioPharma Credit
- 1 hour ago Mountview Estates
- 2 hours ago PayPoint
- 2 hours ago Aviva
- 2 hours ago Reckitt Benckiser Group